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Abstract - RNA interference (RNAi) technology has become a novel tool for silencing gene expression in cells or 
organisms. RNA interference is the process that double-stranded RNA induces the homology-dependent 
degradation of cognate mRNA mediated by 21-23 nucleotide short interfering RNA (siRNA). RNA interference is 
a powerful mechanism of gene silencing that underlies many aspects of eukaryotic biology.  On the molecular 
level, RNAi is mediated by a family of ribonucleoprotein (RNP) complexes called RNA-Induced Silencing 
Complexes (RISCs), which can be programmed to target virtually any nucleic acid sequence for silencing. The 
ability of RISC to locate target RNAs been co-opted by evolution many times to generate a broad spectrum of 
gene silencing pathways. The study about the Silencing of gene expression by siRNA is rapidly becoming a 
powerful tool for genetic analysis and represents a potential strategy for therapeutic product development. In this 
study, the applications of siRNA expressing recombinant adenovirus system in plants, animals and in cancer gene 
therapy are given importance with its modifications. 




Gene silencing is a general term describing epigenetic processes of gene regulation. The term gene silencing is 
generally used to describe the "switching off" of a gene by a mechanism other than genetic modification. That is, a gene which 
would be expressed (turned on) under normal circumstances is switched off by machinery in the cell. Genes are regulated 
either at the transcriptional or at the post-transcriptional level. Transcriptional gene silencing is the result of histone 
modifications, creating an environment of heterochromatin around a gene that makes it in accessible to transcriptional 
machinery (RNA polymerase, transcription factors, etc.). Post-transcriptional gene silencing is the result of mRNA of a 
particular gene being destroyed or blocked. The destruction of the mRNA prevents translation to form an active gene product 
(in most cases, a protein). A common mechanism of post-transcriptional gene silencing is RNAi.  Both transcriptional and 
post-transcriptional gene silencing are used to regulate endogenous genes. Post-transcriptional gene silencing is now regarded 
as an ancient self-defense mechanism of eukaryotic cells to limit the expression of invaded gene products (e.g., those 
associated with viral infection) and as a regulator of endogenous gene expression (Gonczy et al., 2000; McManus et al., 2002). 
RNA interference (RNAi) is a recently discovered RNA-silencing process that occurs in plants and animals.  
RNAi is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by the 
generation of dsRNA molecules homologous in sequence to the silenced gene (Fire et al., 1998). Mechanisms of gene silencing 
also protect the organism's genome from transposons and viruses. Gene silencing thus may be part of an ancient immune 
system protecting from such infectious DNA elements.  RNA interference has become widely used as an experimental tool to 
analyze the function of mammalian genes, both in vitro and in vivo. RNAi is a relatively new discovery for inhibiting gene 
expression and is considered as one of the most important recent discoveries in molecular biology (Abdelrahim et al., 
2006).The discovery of 21-23 nucleotide RNA duplexes called small interference RNA be one of the transforming events in 
biology in the past decade. Production of siRNAs that bind to and induce the degradation of specific endogenous mRNAs is 
now recognized as a mechanism that is widely employed by eukaryotic cells to inhibit protein production at a 
posttranscriptional level. RNAi can result in gene silencing or even in the expulsion of sequences from the genome. It is a 
naturally occurring biological process that is highly conserved among multi cellular organisms diverse as plants, worms, yeast, 
and humans. 
The asymmetry of the siRNA duplex determines which strand enters Dicer to assemble RISC and to induce target-
specific mRNA cleavage. A number of studies have evaluated the extent of gene inhibition specificity achieved with siRNA, in 
most cases indicating selectivity but not an absolute selectivity (Chi et al., 2003; Jackson et al., 2003; Kariko et al., 2004; 
Semizarov et al., 2003; Sledz et al., 2003). In fact, it can be difficult to distinguish between an off-target effect on the wrong 
gene and downstream biological consequences from RNAi silenced genes. The siRNA oligonucleotides were originally 
identified as short dsRNA fragments generated by RNAi machinery called Dicer that processes long dsRNA, such as from a 
viral infection, into siRNA fragments. These siRNA were found to be an active intermediate used a second piece of the 
machinery, called RISC, to select mRNA for degradation, (Bantounas et al., 2004; Lu et al., 2003; McManus et al., 2002). The 
mechanism for miRNA appears to be similar but not identical to that of siRNA. Cancer research is a dynamic and exciting 
area for the application of siRNA inhibitors. 
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Figure 1. Mechanism for siRNA mediated gene silencing
Lu et al. (2003) research in many different therapeutic areas is invoking application of siRNA for use as a research tool for the 
validation of gene functions.Different biochemical, pharmacological, and histological assays have been used to determine the 
effects of siRNA inhibition of specific genes and to analyze the phenotypic changes in cells. Currently, the use of siRNA to 
characterize gene function, and potential therapeutic drug targets is a highly promising application for this technology (Lu et 
al,. 2003). Selective gene knockdown can be used to identify critical genes and/or pathways that can be targeted by siRNA, 
drugs and their combinations for treatment of various disease including cancers .It can be proposed that gene silencing is the 
critical precursor in cancer, as it changes the dynamic interplay between de novo methylation and demethylation of the CpG 
island and tilts the balance to favour hypermethylation and chromatin inactivation. RNAi has been widely used in mammalian 
cells to define the functional roles of individual genes, particularly in disease. RNAi is an incredibly potent mechanism, 
requiring just a few molecules of dsRNA per cell to trigger gene silencing (Fire et al., 1998). It appears to be an evolutionary 
well-conserved biological mechanism, occurring in many organisms, including Arabidopsis and other plants, Drosophila 
(Misquitta et al., 1999), C. elegans, T. brucei (Ngo et al., 1998), hydra (Lohmann et al., 1999), plan aria (Sanchez-Alvarado et al., 
1999), zebra fish (Li et al., 2000) mice (Wianny et al., 2000) and human cells. A key to the characterization of gene function by 
reverse genetics is down-regulation of endogenous genes via post-transcriptional gene silencing (PTGS). Among different 
types of PTGS, RNA interference (RNAi) denotes a sequence-specific gene-silencing mechanism that is initiated by the 
introduction of double-stranded RNA (dsRNA), homologous in sequence to the silence gene, which triggers degradation of 
mRNA (Filipowicz et al,. 2005). RNAi utilizes the endonuclease Dicer to generate small interfering RNAs (siRNAs) from 
dsRNA. The RNAi induced silencing (RISC) complex then destroys specific target mRNAs based on sequence 
complementarities with the siRNA. RNAi based silencing is an excellent strategy for reverse genetics in plants (Small, 2007). It 
has become a powerful tool to silence the expression of target genes and study their loss of function phenotype, allowing 
analysis of gene function when mutant alleles are not available 
 
Gene Silencing in Plants  
 In plants, RNAi plays a role in cellular defense, protecting the cell from inappropriate expression of repetitive 
sequences, transposable elements, and virus infections (Li et al., 2001). Post-transcriptional gene silencing provides plants an 
adaptive immune system that recognizes pathogenic nucleic acids such as those derived from viruses and inactivates them via 
cleavage of their RNAs (Vance and Vaucheret, 2001; Voinnet, 2001; Waterhouse et al., 2001). RNAi holds potential too in 
genetic engineering of crop plants particularly, targeting to reduce level of natural toxin products. The techniques are 
advantageous in plants for their stable and heritable RNAi phenotype. The application of RNAi proved successful in a major 
way, in cotton plant (Kumar et al., 2006). The cotton seeds are rich in dietary protein but unsuitable for human consumption 
because of its toxic terpenoid product, gossypol. RNAi has been used to produce cotton stocks with seeds containing lower 
levels of delta-cadinene synthase, a key enzyme in gossypol production, without affecting the enzyme's production in other 
parts of the plant, where gossypol is important in preventing damage from plant pests. (Siritunga and Sayre, 2003). Efforts 
have been also directed to improve many other useful crop plants, keeping in view a specific target as above, by use of RNAi. 
(Le et al., 2006). Agricultural researchers have been able to suppress the expression of gossypol, a toxic protein, in cotton seed to 
a level considered to be safe for consumption, thus raising its potential as a dietary source of protein using RNAi technology. 
Down-regulation of flavonoid30-hydroxylase gene expression by virus-induced gene silencing in soybean reveals the 
presence threshold mRNA level of the sf30h1 gene associated with pubescence pigmentation in soybean and that its 
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mechanisms may be similar to those of other genes involved in flavonoid biosynthesis. The production of siRNA is a hallmark 
of the occurrence of RNA silencing that involves the sequence-specific degradation of a target mRNA (Hamilton and 
Baulcombe, 1999). Gel-blot analyses of the low- molecular-weight RNA fraction from CMV-A1: F30H-infected To7B plants 
showed that siRNAs that hybridized to the sf30h1 gene probe accumulated in leaf tissues as observed previously in CMV-
A1:F30H-infected greenhouse-grown plants (Nagamatsu et al., 2007). Empty vector-infected plants showed no sf30h1 siRNA 
accumulation. These observations suggest that the reduced sf30h1 mRNA level results from the specific degradation of sf30h1 
mRNA by VIGS (virus-induced gene silencing). 
The strawberry fruit allergen Fra a is the member of the Bet vl superfamily named after the major birch pollen 
allergen and is ranked among a subfamily of pathogenesis-related proteins (PR-10, Munoz et al., 2010). To study the link 
between Fra an expression, Slavonoid and anthocyanin formation Fra a gene expression in strawberry fruit was downregulated 
by RNAi targeted to Fra a. Quantitative PCR (qPCR) analysis confirmed the efficient downregulation of Fra an isoforms. 
  
Gene Silencing in Animals 
An alternative to transgenic animals for the study of the function of specific genes is the use of RNA interference, a 
post-transcriptional gene-silencing mechanism based on the degradation of mRNA (Fire et al., 1998 Hannon, 2002). Reports 
on in vivo experiments of siRNA in cancer are growing. When nude mice were implanted with colon adeno carcinoma cells, 
the survival of these mice was greatly prolonged by pre treating the cells with siRNA against hcatenin (Verma et al., 2003). 
Similarly, silencing of the oncogene H-Ras led to the inhibition of in vivo tumor growth of human ovarian cancer in mice 
(Yang et al., 2003). 
Makimura et al. (2002) used local injection of siRNA against the gene expressing agouti-related protein, into the 
hypothalamic actuate nucleus of adult mice, which resulted in down-regulation of the protein by as much as 50% within 24 h 
of injection, leading to a marked increase in the overall metabolic rate. Cellular introduction of siRNA encoding for AMPA 
glutamate receptor 2 or cyclo-oxygenase 1 into the hippo campal CA1 region and visual cortex of neonatal rats using 
electroporation has also been shown to down-regulate the target mRNA, but again was only local and transient (Akaneya et al., 
2005). As most proteins are not localized in a single region of the brain and they commonly have long half-lives, repeated 
administration of siRNA aided with electroporation would be needed for this purpose which is expensive, time consuming 
and traumatic (Bonnafous et al., 1999; Gehl et al., 2002). Tessitore et al. (2006) showed that mouse RHO mRNA could be 
knocked down in the retina of a living rat. SiRNA301 was created for use in a canine model of ADRP containing T4R 
rhodopsin (Kijas et al., 2002). Tessitore et al. (2006) used AAV5 containing the U6 promoter to deliver a shRNA preferentially 
targeting the mouse P23H RHO transgene. Expression of this allele-specific siRNA reduced the mutant RHO mRNA in P23H 
line 3 rats and, presumably, should have decreased the level of P23H rhodopsin. However, suppression of the P23H RHO 
allele did not lead to the rescue of vision in these transgenic animals. 
In a mouse model of sepsis, it has been shown that pretreatment with TNF a-specific siRNAs injected 
intraperitoneally was able to increase survival rate six fold after lethal lipo polysaccharide challenges (Sorensen et al., 2003). 
Similarly, one of the first experiments to demonstrate the therapeutic potential of RNAi used fas-specific siRNAs to protect 
mice against fulminant hepatitis (Song et al., 2003) and another study reported that caspase 8-specific siRNA treatment also 
prevented acute liver failure (Zender et al., 2003). These studies illustrate the concept that siRNAs might be used effectively to 
control acute responses whether that means limiting dangerous, uncontrolled inflammation or preventing hepatocyte 
apoptosis and preserving liver function. Chemically stabilized and cholesterol-conjugated siRNAs have been shown to silence 
endogenous genes by means of a systemic delivery of the modified siRNA into mouse models (Soutschek et al., 2004). 
 
Gene Silencing in The Treatment of Cancer 
  Cancer is a multi step genetic and epigenetic disease with a complex etiology. Cancer cells have been characterized 
with several defects such as mutations, down-regulation, over-expression and deletions of oncogenes and tumor suppressor 
genes (Hao et al., 1993). The siRNA-based gene silencing method is highly selective and efficient. However, clinical translation 
of this approach faces formidable challenges to overcome (Chowdhury, 2011; Katakowski et al., 2011; Pecot et al., 2011). The 
ability of siRNAs to silence specific oncogenic variants while sparing the wild-type products of genes has been demonstrated 
for K-RasV12 in human pancreatic carcinoma (Brummelkamp et al., 2002). Similarly, a single point mutation in the tumor 
suppressor p53 was effectively discriminated using siRNAs (Martinez et al., 2002), resulting in the targeted destruction of the 
mutant, but not the wild-type product. In uterine cancers, specific knockdown of Akt isoforms 2 and 3, but not 1 using siRNA 
technology, was shown to significantly reduce the resistance of the endometrial KLE cells to cisplatin-induced apoptosis 
(Gagnon et al., 2004). Chow et al. (2004) used siRNA to identify endo-exonuclease (a protein involved in the recombination 
repair process of the DNA double-stranded break pathway, which is over expressed in a variety of cancer cells), as a potential 
anticancer target. 
 Karasarides et al. (2004) showed that B-RAF depletion by siRNA blocked ERK activity, inhibited DNA synthesis, 
and induced apoptosis in three melanoma cell lines. Many studies indicate that Rho GTPases are important in malignant 
transformation and angiogenesis and represent good anticancer targets (Aznar et al., 2004; Pille et al., 2005) used anti-RhoA 
and anti-RhoC siRNAs to block the Rho signaling pathway and demonstrated that the siRNAs inhibited cell proliferation and 
invasion more effectively than do conventional blockers of Rho signaling (e.g., HMG-CoA reductive inhibitors), both in vitro 
and in vivo. Another example of VEGF (Vascular endothelial growth factor) targeting is bevasiranib, a drug molecule already 
in Phase 3 clinical trials in patients with age-related macular degeneration (AMD). AMD is caused by the abnormal growth of 
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blood vessels behind the retina leading to loss of vision (Bonetta, 2009). In Phase 1 and 2 clinical trials, bevasiranib, after being 
administered directly into the eye (intravitreal injection), did not affect the patient systemically, but locally inhibited the 
overgrowth of blood vessels that would otherwise lead to vision loss. 
Bcl-2 and xIAP are antiapoptotic factors and the sensitivity of MCF-7 breast cancer cells to treatment with the drugs 
etoposide and doxorubicin is increased after silencing of bcl-2 or xIAP by siRNA. Treatment of these cells with both siRNAs 
decreases the number of viable cells and increased cellular apoptosis. These studies suggest that combination therapy that 
includes traditional chemotherapies co-administered with specific siRNAs may be a highly effective therapy for cancer.  Single 
and combinatorial c-onc siRNAs combined with cationic lipid complexes have been transfected into HeLa, lung adeno 
carcinoma, hepatoma, ovarian carcinoma, and melanoma cells. The results showed that siRNAs-dependent down regulation of 
bcl-2, cdk-2, mdm-2, pkc-5, tgf-71, H-ras, vegf, and gfp mRNA expression differentially suppressed proliferation of these 
cancer cell lines, many oncogenes are potential molecular targets for human cancer treatment by siRNAs.  
SiRNA silencing of double-strand break repair proteins, such as the DNA-dependent protein kinase catalytic subunit, 
confer enhanced radio and chemo sensitivity to tumor cells (Collis et al., 2003; Peng et al., 2002). RNAi might also complement 
chemotherapy in the treatment of patients that have developed multi drug resistance. While over 30% of cancer patients 
develop resistance to chemotherapeutic agents due to an over expression of the multi drug resistance gene (MDR1) Tsuruo et 
al. (2003). RNAi-mediated suppression of MDR1 has been shown to re-sensitize cells to the effects of chemotherapy (Nieth et 
al., 2003; Yague et al., 2004).  Hence, if RNAi effectors could be specifically delivered to tumors, these cells could be made 
preferentially sensitive to traditional cancer therapies. 
In ovarian cancer, siRNA technology has been employed to inhibit Her-2/neu expression in vitro resulting in 
decreased cell proliferation, increased apoptosis, increased G0/G1 arrest, and decreased tumor growth .Inhibition of Her-
2/neu by RNAi also resulted in decreased expression of VEGF and increased expression of the antiangiogenic factor, 
thrombospondin-1 (Yang et al., 2004). Over expression of p-glycoprotein (p-gp) and glutathione S-transferase (GST) is a 
known mechanism for multi drug resistance in ovarian cancer. Using these targets, siRNAs were delivered against p-gp and 
GST resulting in the restoration of cisplatin sensitivity in vitro. In the future, siRNA may be used as chemo sensitizing agents 
in patients who have developed drug resistance. 
 SiRNA targeting Akt in drug resistant endometrial cancer cell lines resulted in restoration of cisplatin sensitivity, 
significant cell death, and identified Akt as a potential chemo sensitizing agent (Gagnon et al., 2004). In contrast, inhibition of 
Cyr61 (CCN1), a protein involved in cell adhesion, apoptosis, and cell growth, by siRNA increased tumor growth in a well 
differentiated endometrial cancer cell line.  RNAi is also efficient in knocking down Polo like Kinase-1 (PLK-1) gene 
expression. The PLK-1 enzyme, which is involved in several functions of cell mitosis, is over expressed in human tumors. 
Application of PLK-1 siRNA leads to a significant decrease in mRNA and protein levels. The authors show that siRNA 
directed against human WT1 gene (siRNAWT1) effectively inhibited WT1 expression and suppressed the growth of the breast 
cancer cells in both dose- and time dependent manner. This finding suggests that WT1 might serve as a molecular target for 
human breast cancer treatment and siRNAWT1 could be used as therapeutic agent for a gene-targeted therapy approach for 
this cancer (Ruxapon Navakanit et al., 2007). Han et al. (2011) describe an alternative to collagen-based hydrogels by exploiting 
the temperature dependent gelling properties of a Chitosan Hydrogel (CH) for siRNA delivery. Chitosan (a linear 
polysaccharide derivative prepared from the exoskeleton (chitin) of crustaceans) hydrogel is biodegradable and biocompatible 
with no immunoinflammatory response in vivo. These properties are ideal for the local delivery of siRNA. Targeted 
microbubbles are successfully used for anticancer gene therapy (Dash et al., 2011). 
 
Conclusions 
RNAi as therapeutic agents is an emerging field in biotechnology. RNA interference is a relatively new discovery for 
inhibiting gene expression and is considered as one of the most important recent discoveries in molecular oncology. This is 
used to treat a variety of disease. Interfereing RNA molecules can perform a range of regulatory cellular functions.  Significant 
progress has been made and can be used for the treatment of disorders ranging from cancer to infectious diseases. The use of 
RNAi in treating a disease by regulating the gene can serve a lot of significance. Efficiency of the therapeutic use of RNAi in 
cancer relies on the development of safe and efficacious delivery systems that introduce siRNA and shRNA expression 
vectors into target tumour cells without disturbing cell homeostasis. In plants and animals it serves as a defence mechanism. It 
will replace the more toxic traditional treatment and it is highly specific. RNA interference and the functions of non-coding 
RNAs represent one of the major scientific discoveries of the past decade. The endogenous functions of these ribonucleotides 
remain to be further discovered and the application of specific gene targeting by small inhibitory RNAs will hopefully replace 
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